AstraZeneca reaffirms 2026 outlook for low double-digit core EPS growth at constant exchange rates

• AstraZeneca reiterated 2026 guidance for mid-to-high single-digit revenue growth, with core EPS expected to rise by a low double-digit percentage.
• Both growth forecasts are at constant exchange rates; the core tax rate is expected at 18%-22%.
• Nine-month revenue rose 7% to $46.88 billion at constant exchange rates; core EPS increased 14% to $8.
• The $80 billion revenue target for 2030 remains on track.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AstraZeneca plc published the original content used to generate this news brief on October 30, 2026, and is solely responsible for the information contained therein.